Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.3.44 (
P-glycoprotein
)
13,344
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
P-glycoprotein
(
P-gp
) overexpression by tumor cells imparts resistance to multiple antineoplastic chemotherapeutic agents (multiple drug resistance). Treatment of tumor cells with chemotherapeutic agents such as anthracyclines, epipodophyllotoxins, and Vinca alkaloids results in induction of
P-gp
expression. This study was performed to determine if clinically relevant antimicrobial drugs (i.e., drugs that are used to treat bacterial infections in cancer patients) other than antineoplastic agents can induce expression of
P-gp
in MCF-7 breast carcinoma cells. Expression of
P-gp
and MDR1 mRNA was determined in samples from MCF-7 cells that were treated in culture with doxorubicin (positive control) and the antimicrobial drugs doxycycline, piperacillin, and cefoperazone. The functional status of
P-gp
was assessed using laser cytometry to determine intracellular doxorubicin concentrations. The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay was used to determine if the cytotoxicity of experimental drugs was related to their ability to induce
P-gp
expression. MCF-7 cells treated with doxycycline (MCF-7/doxy) were stimulated to overexpress
P-gp
, whereas cells treated with piperacillin and cefoperazone did not overexpress
P-gp
. MCF-7/doxy cells were compared to a positive-control subline, MCF-7/Adr, previously selected for doxorubicin resistance, and to MCF-7 cells treated with doxorubicin (MCF-7/doxo). All three sublines overexpressed
P-gp
and MDR1 mRNA and accumulated less intracellular doxorubicin than did control MCF-7 cells.
P-gp
expression was induced only by experimental drugs that were cytotoxic (doxorubicin and doxycycline).
Doxycycline
, a drug that has been used for treatment of bacterial infections in cancer patients, can induce functional
P-gp
expression in cancer cells, resulting in multidrug resistance.
...
PMID:Doxycycline induces expression of P glycoprotein in MCF-7 breast carcinoma cells. 1185 Feb 58
The impact of
P-glycoprotein
(
P-gp
) on the distribution of quinine between brain and plasma was studied experimentally in mice. Administration of quinine (20mg/kg, i.v.) to mdrla knockout mice resulted in enhanced brain concentrations of quinine as compared to the wild-type mice (7.9+/-1.4 microg/g versus 1.6+/-0.8 microg/g, respectively). Quinine concentrations and quinine-to-3-hydroxyquinine ratio in plasma were similar in normal and
P-gp
-deficient mice. The effect of intravenously administered drugs before quinine (20mg/kg, i.v.) was evaluated on brain uptake and biotransformation of quinine in mice. Cyclosporine A (50 mg/kg), erythromycine (40 mg/kg), verapamil (5mg/kg) or mefloquine (20 mg/kg) increased the brain-to-plasma quinine concentration ratio (by factors of 3.8-, 1.8-, 1.9- and 2.5-fold, respectively) and the quinine-to-3-hydroxyquinine ratio in plasma (by factors 2.1-, 3.7-, 1.8- and 2.0-fold, respectively). After cinchonine (40 mg/kg) and halofantrine (40 mg/kg) pre-treatment, the brain-to-plasma ratio for quinine increased by factor of 2.3 and 1.8, respectively without changes of quinine or metabolite concentrations in plasma.
Doxycycline
(20 mg/kg), artesunate (50 mg/kg) or artemether (50 mg/kg) did not alter quinine disposition. These results confirm in vivo that quinine is a substrate for mdr1a
P-gp
. Drug associations led not only to metabolic interactions but also increased quinine uptake by tissues protected by
P-gp
. Such interactions may have implications for the improvement of chemotherapy but should be also taken into account for potential enhancement of adverse effects.
...
PMID:Increased uptake of quinine into the brain by inhibition of P-glycoprotein. 1769 30